JAK
Cat. No. | Product Name | CAS No. | Information |
---|---|---|---|
CSN26377 | WHI-P258 | 21561-09-1 | WHI-P258 is a quinazoline compound that binds to the active site of JAK3 with an estimated Ki of 72 µM, but does not inhibit JAK3 and does not affect the thrombin-induced aggregation of platelets even at 100 μM[1][2]. |
CSN12405 | Fedratinib | 936091-26-8 | TG 101348 is an inhibitor of JAK2 with an IC of 6 nM and also inhibits related kinases FLT3, RET, and JAK3 with less potent activity, having IC values of 25, 17 and 169 nM, respectively. |
CSN23146 | TCJL37 | 1258294-34-6 | TCJL-37 is a potent TYK2 inhibitor. |
CSN27609 | SC99 | 882290-02-0 | SC99 is a selective inhibitor of JAK2-STAT3 activation. |
CSN24499 | SAR-20347 | 1450881-55-6 | SAR-20347 is a TYK2 and JAK inhibitor with IC50 values of 0.6, 23, 26 and 41nM for TYK2, JAK1, JAK2 and JAK3, respectively. |
CSN16800 | Pyridone 6 | 457081-03-7 | Pyridone 6 is a potent and selective inhibitor of JAK1 (IC5015 nM, murine JAK1), JAK2 (IC501 nM), JAK3 (Ki5 nM), and Tyk2 (IC501 nM) displaying significantly weaker affinities(130 nM to 10 mM) for other protein tyrosine kinases. |
CSN23211 | ZM 449829 | 4452-06-6 | Potent, selective JAK3 inhibitor |
CSN19685 | ((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)(pyrrolidin-1-yl)methanone | 1262832-74-5 | PF-956980 is a FGF1 receptor antagonist, a PDGF receptor modulator, an Flt3 tyrosine kinase modulator, and a VEGF antagonist used as immunosuppressive agent. |
CSN26122 | Ropsacitinib (PF-06826647) | 2127109-84-4 | PF-06826647 is a selective TYK2 inhibitor It is being tested in moderate-to-severe psoriasis in a Phase II clinical trial. |
CSN23226 | Brepocitinib P-Tosylate | 2140301-96-6 | PF-06700841 P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. PF-06700841 P-Tosylate also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively[1]. |
CSN26398 | Ritlecitinib | 1792180-81-4 | PF-06651600 is an orally active and selective JAK3 inhibitor with an IC50 of 33.1 nM. |
CSN19687 | PF-06263276 | 1421502-62-6 | PF-06263276 is a potent and selective pan-JAK inhibitor which is suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. |
CSN19239 | Oclacitinib maleate | 1640292-55-2 | Oclacitinib Fumarate is a potent JAK inhibitor with IC50 value ranging in 10-99 nM for JAK family members, most potent against JAK1 with IC50 value of 10 nM. |
CSN23158 | TCS 21311 | 1260181-14-3 | NIBR3049, also known as TCS-21311, is a potent and selective JAK3 inhibitor IC50 values of 8 nM.. |
CSN11462 | Mollugin | 55481-88-4 | Mollugin, a natural product isolated and purified from the roots of Rubia cordifolia L., may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. |
CSN23767 | JAK3-IN-6 | 1443235-95-7 | JAK3-IN-6 is an irreversible, potent and highly selective JAK3 inhibitor with IC50 value of 0.15 nM, 4300-fold selective for JAK3 over JAK1 in enzyme assays. |
CSN24175 | JAK/HDAC-IN-1 | 2284621-75-4 | JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor with improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematological cell lines. |
CSN22435 | JAK-IN-1 | 1334673-53-8 | JAK-IN-1 is a JAK123 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1. |
CSN20267 | JAK Inhibitor C35 | 1400687-19-5 | JAK inhibitor C6 is a potent dual JAK13 inhibitor providing exceptional biochemical potency against JAK1 and JAK3 while maintaining good selectivity against JAK2 and Tyk2. |
CSN22434 | JAK-IN-5 | 2096999-92-5 | JAK inhibitor 1 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. |
CSN33128 | Izencitinib | 2051918-33-1 | Izencitinib is an orally active, non-selective and gut-restricted JAK inhibitor. |
CSN26688 | 2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide | 1258292-64-6 | GDC046 was an effective and selective oral biouse inhibitor of TYK2, with Ki values of 4.8 nM, 83.8 nM, 27.6 nM and 253 nM against TYK2, JAK1, JAK2 and JAK3, respectively. |
CSN23319 | FM-381 | 2226521-65-7 | FM381 is a potent covalent reversible inhibitor of JAK3 targeting the unique Cys909 at the gatekeeper position +7 in JAK3. FM-381 has an IC50 of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively. |
CSN26689 | FM-479 | 2226521-64-6 | FM-479 is the negative control of FM-381 (HY-102046) and has no activity on JAK3 or other kinases[1]. FM-381 is a potent covalent reversible inhibitor of JAK3 targeting the unique Cys909. FM-381 has an IC50 of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively. |
CSN27527 | Fedratinib hydrochloride hydrate | 1374744-69-0 | Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research. |
CSN21229 | Delgocitinib | 1263774-59-9 | Delgocitinib is a novel and specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. |
CSN14154 | Dehydrocrenatidine | 65236-62-6 | Dehydrocrenatidine, a natural product isolated and purified from the barks of Picrasma quassioides, is a JAK-specific inhibitor, which inhibits JAK2-JH1 kinase activity in vitro , represses constitutively activated JAK2 and STAT3, as well as interleukin-6-, interferon--, and interferon--stimulated JAK activity, and STAT phosphorylation, and suppresses STAT3 and STAT1 downstream gene expression. |
CSN17436 | Momelotinib sulfate | 1056636-06-6 | CYT387 sulfate is an ATP-competitive inhibitor of JAK1JAK2 with IC50 of 11 nM18 nM, 10-fold selectivity versus JAK3. |
CSN13153 | Momelotinib | 1056634-68-4 | CYT387 is a selective and potent ATP-competitive JAK1/2 inhibitor with IC50 values of 11nM and 18nM, respectively, with less potency against JAK3 with IC50 value of 155 nM. |
CSN19970 | Curculigoside | 85643-19-2 | Curculigoside, a natural product isolated and purified from the rhizomes of Curculigo orchioides Gaertn., can prevent bone loss, improve osteogenesis and inhibit osteoclastogenesis of hAFSCs, suggesting its potential use to regulate hAFSC osteogenic differentiation for treating bone disorders.Curculigoside can also promote calcium deposition and increase the levels of ALP and Runx2 in osteoblasts under oxidative stress via anti-oxidative character, and possesses potent antioxidant properties against oxidative stress insults. |
CSN16269 | CTX-0294885 | 1439934-41-4 | CTX-0294885 is a bisanilino pyrimidine and exhibits inhibitory activity against a broad range of kinases in vitro, further developed into a Sepharose-supported kinase capture reagent. CTX-0294885 is a broad spectrum kinase inhibitor that inhibited FAK, FLT3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 (IC50s = 4, 1, 3, 28, 2, 18, and 3 nM, respectively) in an initial screen. |
CSN13905 | Cerdulatinib | 1198300-79-6 | Cerdulatinib is a multiple tyrosine kinase inhibitor with IC50 values of 12 nM6 nM8 nM and 0.5 nM, for JAK1JAK2JAK3 and TYK2, also shows potency against MST1, ARK5, MLK1, Fms. Syk, etc. with IC50 values ranging in 4-51 nM. |
CSN13724 | AG490 | 133550-30-8 | AG-490 is a broad-spectrum inhibitor that has several targets including EGFR (IC50 2 M), ErbB2 (IC50 13.5 M), STAT3 and JAK2. |
CSN24191 | Abrocitinib | 1622902-68-4 | Abrocitinib is a potent and selective JAK1 inhibitor with IC50s of 29 and 803nM for JAK1 and JAK2, respectively. |
CSN27798 | G5-7 | 939681-36-4 | |
CSN27819 | RO495 | 1258296-60-4 | |
CSN32457 | Ivarmacitinib | 1445987-21-2 | |
CSN32470 | Gusacitinib | 1425381-60-7 | |
CSN43357 | Tyk2-IN-3 | 1779493-12-7 | |
CSN42980 | JAK-IN-11 | 916742-11-5 | |
CSN67834 | Ilunocitinib | 1187594-14-4 |